A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers
Pre-publication versions of this article are available by contacting email@example.com.
|28 Aug 2018||Submitted||Original manuscript|
|18 Oct 2018||Reviewed||Reviewer Report - Peter Lichtlen|
|23 Oct 2018||Reviewed||Reviewer Report - Qi Zhao|
|19 Nov 2018||Author responded||Author comments - Tracy L Staton|
|Resubmission - Version 2|
|19 Nov 2018||Submitted||Manuscript version 2|
|23 Nov 2018||Reviewed||Reviewer Report - Peter Lichtlen|
|30 Nov 2018||Author responded||Author comments - Tracy L Staton|
|Resubmission - Version 3|
|30 Nov 2018||Submitted||Manuscript version 3|
|10 Dec 2018||Editorially accepted|
|7 Jan 2019||Article published||10.1186/s12890-018-0763-9|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.